Stock Analysis

3 US Stocks That May Be Trading Below Their Estimated Value In December 2024

Published

As the United States stock market navigates a challenging landscape marked by fluctuating inflation data and cautious Federal Reserve policies, investors are on the lookout for opportunities that may arise from these volatile conditions. In such an environment, identifying stocks potentially trading below their estimated value can be a prudent strategy for those seeking to capitalize on market inefficiencies.

Top 10 Undervalued Stocks Based On Cash Flows In The United States

NameCurrent PriceFair Value (Est)Discount (Est)
Clear Secure (NYSE:YOU)$26.66$53.1449.8%
Oddity Tech (NasdaqGM:ODD)$43.76$84.5548.2%
Western Alliance Bancorporation (NYSE:WAL)$84.62$165.2248.8%
HealthEquity (NasdaqGS:HQY)$94.95$189.2249.8%
Advanced Energy Industries (NasdaqGS:AEIS)$113.00$219.0048.4%
WEX (NYSE:WEX)$169.39$332.0549%
LifeMD (NasdaqGM:LFMD)$5.04$9.7948.5%
South Atlantic Bancshares (OTCPK:SABK)$15.02$29.9849.9%
Freshpet (NasdaqGM:FRPT)$143.71$283.1249.2%
Progress Software (NasdaqGS:PRGS)$66.38$129.5248.7%

Click here to see the full list of 179 stocks from our Undervalued US Stocks Based On Cash Flows screener.

Let's uncover some gems from our specialized screener.

HashiCorp (NasdaqGS:HCP)

Overview: HashiCorp, Inc. provides multi-cloud infrastructure automation solutions globally and has a market capitalization of approximately $7.01 billion.

Operations: The company's revenue segment is Internet Software & Services, generating $654.89 million.

Estimated Discount To Fair Value: 13.6%

HashiCorp is trading at US$34.27, below its estimated fair value of US$39.66, indicating it may be undervalued based on cash flows. Despite recent shareholder dilution, the company shows promising revenue growth forecasts of 13.9% annually, outpacing the broader U.S. market's 9.1%. Recent earnings reports reveal improved financials with a reduced net loss and increased revenue compared to last year, suggesting a positive trend towards profitability within three years.

NasdaqGS:HCP Discounted Cash Flow as at Dec 2024

HealthEquity (NasdaqGS:HQY)

Overview: HealthEquity, Inc. operates technology-enabled services platforms for consumers and employers in the United States, with a market cap of approximately $8.23 billion.

Operations: The company generates revenue from its Pharmacy Services segment, which amounts to $1.15 billion.

Estimated Discount To Fair Value: 49.8%

HealthEquity, trading at US$94.95, is significantly undervalued with an estimated fair value of US$189.22. Despite recent insider selling and a one-off legal settlement impacting earnings, the company shows robust financial health with revenue growth outpacing the U.S. market at 10.1% annually and earnings expected to grow by 39.8% per year over the next three years, supported by strong cash flow forecasts and strategic share buybacks totaling US$60 million recently completed.

NasdaqGS:HQY Discounted Cash Flow as at Dec 2024

Granite Ridge Resources (NYSE:GRNT)

Overview: Granite Ridge Resources, Inc. is a non-operated oil and gas exploration and production company with a market capitalization of $809.31 million.

Operations: The company's revenue segment consists of $358.52 million from oil and natural gas development, exploration, and production.

Estimated Discount To Fair Value: 26.1%

Granite Ridge Resources, trading at US$6.19, is undervalued with a fair value estimate of US$8.38. Despite a dividend yield of 7.11% not covered by earnings or free cash flows, its revenue and earnings are forecast to grow faster than the U.S. market at 17.7% and 35.6% per year respectively over the next three years, although recent profit margins have decreased significantly due to large one-off items affecting financial results.

NYSE:GRNT Discounted Cash Flow as at Dec 2024

Next Steps

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com